Abstract

Pretransplant detection of KMT2Ar measurable residual disease ≥0.001% by quantitative polymerase chain reaction was associated with significantly inferior posttransplant survival (2-year relapse-free survival 17% vs 59%; P = .001) and increased 2-year cumulative incidence of relapse (75% vs 25%, P = .0004).

1.
Döhner
H
,
Wei
AH
,
Appelbaum
FR
, et al
.
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
.
Blood
.
2022
;
140
(
12
):
1345
-
1377
.
2.
Hernandez-Sanchez
A
,
Gonzalez
T
,
Sobas
M
, et al
.
Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications—a HARMONY study
.
Leukemia
.
2024
;
38
(
9
):
1929
-
1937
.
3.
Menghrajani
K
,
Gomez-Arteaga
A
,
Madero-Marroquin
R
, et al
.
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-adverse-risk, and KMT2A-rearranged AML
.
Blood Adv
.
2022
;
6
(
3
):
828
-
847
.
4.
Scholl
C
,
Breitinger
H
,
Schlenk
RF
, et al
.
Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia
.
Genes Chromosomes Cancer
.
2003
;
38
(
3
):
274
-
280
.
5.
Heuser
M
,
Freeman
SD
,
Ossenkoppele
GJ
, et al
.
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
.
Blood
.
2021
;
138
(
26
):
2753
-
2767
.
6.
Huang
S
,
Yang
H
,
Li
Y
, et al
.
Prognostic significance of mixed-lineage leukemia (MLL) gene detected by real-time fluorescence quantitative PCR assay in acute myeloid leukemia
.
Med Sci Monit
.
2016
;
22
:
3009
-
3017
.
7.
Liu
J
,
Wang
Y
,
Xu
LP
, et al
.
Monitoring mixed lineage leukemia expression may help identify patients with mixed lineage leukemia—rearranged acute leukemia who are at high risk of relapse after allogeneic hematopoietic stem cell transplantation
.
Biol Blood Marrow Transplant
.
2014
;
20
(
7
):
929
-
936
.
8.
Ommen
HB
,
Hokland
P
,
Haferlach
T
, et al
.
Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene
.
Br J Haematol
.
2014
;
165
(
5
):
618
-
628
.
9.
Meyer
C
,
Larghero
P
,
Almeida Lopes
B
, et al
.
The KMT2A recombinome of acute leukemias in 2023
.
Leukemia
.
2023
;
37
(
5
):
988
-
1005
.
10.
Meyer
C
,
Burmeister
T
,
Groger
D
, et al
.
The MLL recombinome of acute leukemias in 2017
.
Leukemia
.
2018
;
32
(
2
):
273
-
284
.
11.
Issa
GC
,
Aldoss
I
,
DiPersio
J
, et al
.
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
.
Nature
.
2023
;
615
(
7954
):
920
-
924
.
12.
Issa
GC
,
Aldoss
I
,
Thirman
MJ
, et al
.
Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)
.
J Clin Oncol
.
2024
:
JCO2400826
.
13.
Abildgaard
L
,
Ommen
HB
,
Lausen
B
,
Hasle
H
,
Nyvold
CG
.
A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia
.
Eur J Haematol
.
2013
;
91
(
5
):
394
-
398
.
You do not currently have access to this content.
Sign in via your Institution